Reuters: Chinese Firm Hires Trump-Linked Lobbying Firm to Avoid US Regulatory Scrutiny
NQ Score
100/100
AI Summary (NQ-processed)
A Chinese pharmaceutical group, Grand Pharmaceutical Group, hired Checkmate, a lobbying firm connected to Donald Trump Jr., to navigate a US regulatory review of its $12 million investment in US startup FastWave. FastWave, which produces laser catheters, sought CFIUS review due to national security concerns and a partnership between Grand Pharmaceutical and a Chinese competitor. CFIUS ultimately rejected FastWave's application for a national security review, siding with Grand Pharmaceutical.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was the amount of Grand Pharmaceutical Group's investment in FastWave?
- A: Grand Pharmaceutical Group invested $12 million in FastWave.
- Q: Which lobbying firm linked to Donald Trump Jr. did Grand Pharmaceutical hire?
- A: Grand Pharmaceutical hired the lobbying firm Checkmate.
- Q: What is the name of the US startup that produces laser catheters?
- A: The US startup is named FastWave.
- Q: Which regulatory body reviewed FastWave's national security application?
- A: The Committee on Foreign Investment in the United States (CFIUS) reviewed the application.
- Q: What decision did CFIUS make regarding FastWave's national security review?
- A: CFIUS rejected FastWave's application for a national security review.